Fore: Stock Predictions Daily Brief · Dec 11, 2025
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
Fore Stock Predictions Daily Brief - 2025-12-11
Target window: 2025-12-18
Top opportunities:
- 1. $PLTR → $196.96 (+5.5%) @ 72% confidence
- 2. $NEM → $99.83 (+4.7%) @ 75% confidence
- 3. $STX → $312.42 (+5.0%) @ 76% confidence
- 4. $GEV → $757.18 (+5.4%) @ 72% confidence
- 5. $APP → $729.12 (+4.3%) @ 73% confidence
- 6. $SLV → $58.44 (+4.2%) @ 74% confidence
- 7. $WDC → $187.77 (+4.0%) @ 76% confidence
- 8. $VRTX → $461.27 (+3.8%) @ 73% confidence
- 9. $REGN → $752.11 (+3.7%) @ 71% confidence
- 10. $CRM → $271.16 (+3.4%) @ 74% confidence
Story beats:
- $PLTR: PLTR surges on $448M Navy contract, stellar Q3 results, AI innovations, and bullish technicals amid Fed rate cuts, eyeing further gains despite valuation risks.
- $NEM: Newmont (NEM) is poised for gains from Fed rate cut, Ahafo North production milestone, strong financials, and bullish technicals in a gold bull market.
- $STX: STX surges on AI data storage demand, HAMR tech traction, strong earnings, and bullish technicals, positioning for continued gains amid IT spend boom.
- $GEV: GEV surges on Investor Day catalysts, AI-driven demand, capital returns, and Fed cuts, outweighing technical overbought risks for ~3-5% weekly upside.
- $APP: AppLovin's strong Q3 beat, AI expansions, $3.2B buyback, bullish technicals, and dovish macro drive compelling upside for investors.
- $SLV: SLV poised for upside on Fed rate cuts, USD weakness, industrial demand surge, supply deficits, and robust $1B ETF inflows amid bullish technicals.
- $WDC: WDC surges on AI-driven storage demand, price hikes, strong earnings, and analyst upgrades, targeting modest near-term upside.
- $VRTX: VRTX poised for upside on imminent povetacicept and JOURNAVX data, Morgan Stanley upgrade, and resilient fundamentals amid biotech caution.
- $REGN: REGN's approvals for Dupixent/Eylea, promising Lynozyfic data, Tessera deal, and analyst upgrades position it for ~3% weekly upside amid biotech tailwinds.
- $CRM: CRM's AI-driven growth, earnings beat, and macro tailwinds position it for 23% upside amid strong technical momentum.
Dashboards + charts: https://fore.markets/aggregated-forecast-report-v2?run_id=2025-12-11
Video + captions also on fore.markets.
⚠️ Not financial advice. Markets involve risk. Terms: fore.markets/tos.html | Privacy: fore.markets/privacy.html.
まだレビューはありません